Coherus Oncology, Inc.
Biopharmaceutical company developing and commercializing immuno-oncology therapies.
CHRS | US
Overview
Corporate Details
- ISIN(s):
- US19249H1032
- LEI:
- Country:
- United States of America
- Address:
- C/O DENNIS M. LANFEAR, 94065 REDWOOD CITY
- Website:
- https://www.coherus.com/
- Sector:
- Manufacturing
Description
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies. The company advances a diversified portfolio of next-generation treatments to improve outcomes for patients with cancer, particularly those with hard-to-treat tumors. Its key commercial product is LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor. LOQTORZI® is the only therapy approved by the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), used either as a single agent or in combination with chemotherapy. Coherus's clinical pipeline includes multiple drug candidates that target the tumor microenvironment.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Coherus Oncology, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Coherus Oncology, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Coherus Oncology, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
